1. Home
  2. ONT vs DCTH Comparison

ONT vs DCTH Comparison

Compare ONT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onterris Inc. Common Stock

ONT

Onterris Inc. Common Stock

N/A

Current Price

$23.41

Market Cap

503.6M

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$19.26

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ONT
DCTH
Founded
2012
1988
Country
United States
United States
Employees
3500
N/A
Industry
Professional Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.6M
578.4M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
ONT
DCTH
Price
$23.41
$19.26
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$21.00
★ $28.60
AVG Volume (30 Days)
477.2K
★ 689.5K
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
93.69
★ 107.53
EPS
N/A
★ 0.21
Revenue
★ $830,538,000.00
N/A
Revenue This Year
N/A
$36.66
Revenue Next Year
$8.91
$20.12
P/E Ratio
★ N/A
$92.43
Revenue Growth
★ 19.26
N/A
52 Week Low
$12.35
$8.49
52 Week High
$24.15
$22.51

Technical Indicators

Market Signals
Indicator
ONT
DCTH
Relative Strength Index (RSI) 75.56 59.41
Support Level $12.62 $14.14
Resistance Level N/A $22.51
Average True Range (ATR) 1.34 1.17
MACD 0.38 0.25
Stochastic Oscillator 89.72 58.96

Price Performance

Historical Comparison
ONT
DCTH

About ONT Onterris Inc. Common Stock

Onterris Inc is an environmental solutions company. The company provides environmental solutions to organizations addressing regulatory, operational, and environmental challenges. Its services include the application of scientific, engineering, and data-driven approaches to support risk management, compliance, and environmental protection, including air, water, and soil.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: